XBIT - エックスバイオテック （XBiotech Inc.） エックスバイオテックXBITのチャート
XBITの企業情報
| symbol | XBIT |
|---|---|
| 会社名 | XBiotech Inc （エックスバイオテック） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Xバイオテック(XBiotech Inc)は臨床段階のバイオ医薬品会社である。同社は各種疾患の治療のために「True Human」モノクローナル抗体の発見と開発に従事する。同社は天然ヒト免疫応答に由来するリード製品候補であるXilonix（MABp1）に焦点を当てる。同社はまた、「True Human」モノクローナル抗体発見プラットフォーム及び製造システムを開発した。Xilonixはインターロイキン-1アルファ（IL-1a）を特異的に中和する治療用抗体である。同社のパイプラインは、癌、血管疾患、炎症性皮膚疾患及び糖尿病等の疾患を治療するための各種ヒト抗体を含む。同社は症候性結腸直腸癌の治療のためにヨーロッパにおいて第III相試験を完了した。同社はまた、血管疾患、II型糖尿病、ざ瘡、乾癬、膿皮症（PG）及び腹水炎（HS）を含む他の炎症状態の臨床試験において、リード製品候補を調査した。 エックスバイオテックはカナダ籍の臨床段階のバイオ医薬品メ―カ―。種々の疾患の治療のための、モノクロ―ナル抗体「True Human」を発見し、パイプラインと生産システムを開発。主要製品候補、インタ―ロイキン-1アルファを中和する治療抗体「MABp1」の開発に注力する。本社は米国テキサス州。 XBiotech is a fully integrated, global biopharmaceutical company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies. XBiotech currently is advancing a pipeline of therapies by harnessing naturally occurring antibodies from patients with immunity to certain diseases. Utilizing natural human immunity as a source of new medicines offers the potential to redefine the standards of care for a wide range of diseases. |
| 本社所在地 | 8201 E. Riverside Drive Building 4 Suite 100 Austin TX 78744 USA |
| 代表者氏名 | John Simard ジョン・シマール |
| 代表者役職名 | Chairman of the Board President Chief Executive Officer Founder |
| 電話番号 | +1 512-386-2930 |
| 設立年月日 | 38412 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2015年 |
| 従業員数 | 51人 |
| url | www.xbiotech.com |
| nasdaq_url | https://www.nasdaq.com/symbol/xbit |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -21.78000 |
| 終値（lastsale） | 3.21 |
| 時価総額（marketcap） | 114981468.12 |
| 時価総額 | 時価総額（百万ドル） 116.41430 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 91.56530 |
| 当期純利益 | 当期純利益（百万ドル） -23.43000 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 XBiotech Inc revenues was not reported. Net loss decreased 49% to $10M. Lower net loss reflects Research and Development decrease of 60% to $4.6M (expense) Salaries and related expenses decrease of 48% to $2.1M (expense) Stock-based Compensation in General decrease of 69% to $497K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.58 to -$0.28. |
XBITのテクニカル分析
XBITのニュース
Let’s Talk About How XBiotech Inc. (NASDAQ: XBIT) Stock Is Doing. 2022/06/20 19:00:00 Marketing Sentinel
In the last trading session, 0.21 million shares of the XBiotech Inc. (NASDAQ:XBIT) were traded, and its beta was 1.41. Most recently the company’s share price was $5.13, and it changed around -$0.13 or -2.47% from the last close, which brings the market valuation of the company to $161.95M. XBIT currently trades at a discount … Let’s Talk About How XBiotech Inc. (NASDAQ: XBIT) Stock Is Doing. Read More »
XBiotech Announces Successful Completion of Phase I portion of Pancreatic Cancer Study 2022/06/20 13:00:00 GlobeNewswire
Novel Natrunix Treatment Shows Promise in Combination Chemotherapy for Treatment of Pancreatic Cancer Novel Natrunix Treatment Shows Promise in Combination Chemotherapy for Treatment of Pancreatic Cancer
Why Are XBiotech Shares Trading Higher Today 2022/04/28 18:53:21 Benzinga
The French authority has signed off XBiotech Inc''s (NASDAQ: XBIT ) multicenter randomized clinical study for Natrunix combined with trifluridine/tipiracil for colorectal cancer. The French National Cancer Institute (INCA) has also awarded a grant to fund all clinical costs for the study. Investigators will combine Natrunix and trifluridine/tipiracil as a new candidate therapy for metastatic colorectal cancer … Full story available on Benzinga.com
XBiotech Announces French National Agency (ANSM) Approval and National Cancer Institute (INSA) funding to Support Phase I/II/III Clinical Study for Natrunix in Combination with Trifluridine/Tipiracil (TASKIN) for Treatment of Metastatic Colorectal Cancer 2022/04/28 13:00:00 Wallstreet:Online
ANSM approves NATRUNIX for INSA funded Phase-I-III Study at 20 Leading Medical Centers in France AUSTIN, Texas, April 28, 2022 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today that the French National Agency for the Safety of Medicines and Health Products [L''Agence nationale de sécurité du médicament et des produits de santé (ANSM)] approved the launch of a multicenter randomized
XBiotech Announces French National Agency (ANSM) Approval and National Cancer Institute (INSA) funding to Support Phase I/II/III Clinical Study for Natrunix™ in Combination with Trifluridine/Tipiracil (TASKIN) for Treatment of Metastatic Colorectal Cancer 2022/04/28 13:00:00 GlobeNewswire
ANSM approves NATRUNIX for INSA funded Phase-I-III Study at 20 Leading Medical Centers in France ANSM approves NATRUNIX for INSA funded Phase-I-III Study at 20 Leading Medical Centers in France
Wells Fargo & Company MN Sells 17,033 Shares of XBiotech Inc. (NASDAQ:XBIT) 2021/12/12 09:38:42 Transcript Daily
Wells Fargo & Company MN reduced its stake in XBiotech Inc. (NASDAQ:XBIT) by 7.5% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 210,484 shares of the biopharmaceutical companys stock after selling 17,033 shares during the period. Wells Fargo & Company []
XBiotech Inc.: XBiotech to Launch Novel Candidate Therapy for Stroke 2021/10/28 16:05:00 FinanzNachrichten
Company Commencing Phase I/II Study to Test Safety and Efficacy of its New Drug Candidate to Reduce Brain Injury After StrokeAUSTIN, Texas, Oct. 28, 2021 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT)
XBiotech to Launch Novel Candidate Therapy for Stroke 2021/10/28 15:59:00 Intrado Digital Media
Company Commencing Phase I/II Study to Test Safety and Efficacy of its New Drug Candidate to Reduce Brain Injury After Stroke Company Commencing Phase I/II Study to Test Safety and Efficacy of its New Drug Candidate to Reduce Brain Injury After Stroke
Citigroup Inc. Has $48,000 Holdings in XBiotech Inc. (NASDAQ:XBIT) 2021/10/23 08:20:41 Transcript Daily
Citigroup Inc. grew its position in XBiotech Inc. (NASDAQ:XBIT) by 72.5% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,881 shares of the biopharmaceutical companys stock after purchasing an additional 1,211 shares during the period. Citigroup Inc.s holdings in XBiotech []
Xbiotech Inc (XBIT) CEO John Simard Sold $1.1 million of Shares 2021/10/16 01:15:01 GuruFocus
Related Stocks: XBIT ,
XBiotech Inc.: XBiotech to Launch Novel Candidate Therapy for Stroke 2021/10/28 16:05:00 FinanzNachrichten
Company Commencing Phase I/II Study to Test Safety and Efficacy of its New Drug Candidate to Reduce Brain Injury After StrokeAUSTIN, Texas, Oct. 28, 2021 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT)
XBiotech to Launch Novel Candidate Therapy for Stroke 2021/10/28 15:59:00 Intrado Digital Media
Company Commencing Phase I/II Study to Test Safety and Efficacy of its New Drug Candidate to Reduce Brain Injury After Stroke Company Commencing Phase I/II Study to Test Safety and Efficacy of its New Drug Candidate to Reduce Brain Injury After Stroke
Citigroup Inc. Has $48,000 Holdings in XBiotech Inc. (NASDAQ:XBIT) 2021/10/23 08:20:41 Transcript Daily
Citigroup Inc. grew its position in XBiotech Inc. (NASDAQ:XBIT) by 72.5% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,881 shares of the biopharmaceutical companys stock after purchasing an additional 1,211 shares during the period. Citigroup Inc.s holdings in XBiotech []